Abu Dhabi Health Services Company (SEHA), a subsidiary of Pure Health, has announced that it has successfully treated a 54-year-old patient with end-stage renal disease (ESRD) undergoing dialysis for thyroid cancer using radioactive therapy.

According to Amac News: The company said that this is a significant breakthrough in the implementation of radioactive iodine treatment for a patient requiring hemodialysis (HD) during isolation, which sets a new precedent for innovative, collaborative and safe healthcare practices.
The practice was a collaborative effort by SEHA Sheikh Khalifa Medical City (SKMC) and SEHA Kidney Care (SKC) specialists, bringing together specialists in nuclear medicine, endocrinology, kidney care, dialysis services, environmental health and safety, and engineering. brings.
Radioactive iodine therapy, the cornerstone of post-surgical thyroid cancer treatment, requires precise dosing based on patient risk stratification.
The multidisciplinary thyroid cancer team agreed with the patient's decision to undergo a total thyroidectomy followed by postoperative radioactive iodine therapy.
This choice was made with the aim of removing and effectively treating thyroid cancer, with a special focus on ensuring the safety and efficacy of dialysis during the patient's radioactive isolation period.